December 10, 2025 (MLN): Liven Pharma Limited (PSX:LIVEN) has entered a significant toll manufacturing agreement with Skywin, a strategic step in the company’s long-term growth trajectory.

According to the company’s on PSX, the partnership will add two high-value segments to Liven’s product line: hormonal medicines and penicillin-based products.

The company states that this development reflects its commitment to delivering greater value to investors and shareholders.

Liven notes that the expansion represents a bold and aggressive move designed to fuel dynamic growth in the coming years.

At the time of writing, Liven Pharma is being traded at Rs56.1, up Rs0.96 (1.74%).